Abstract
Despite a growing understanding of the pathogenesis and spectrum of Epstein-Barr virus (EBV) and EBV-associated post-transplant lymphoproliferative disease (PTLD) in organ transplant recipients, the optimal management of this complication remains controversial. The absence of comparative data evaluating potential therapeutic strategies explains the lack of uniformly accepted guidelines for the management of PTLD. The purpose of this review is to provide an overview of potential therapies and offer a set of guidelines for the management of EBV-associated PTLD in children.
MeSH terms
-
Antiviral Agents / therapeutic use
-
Child
-
DNA, Viral / analysis
-
Drug Therapy, Combination
-
Epstein-Barr Virus Infections / pathology
-
Epstein-Barr Virus Infections / therapy*
-
Epstein-Barr Virus Infections / virology
-
Herpesvirus 4, Human / drug effects
-
Herpesvirus 4, Human / genetics
-
Humans
-
Immunosuppressive Agents / therapeutic use
-
Interferons / therapeutic use
-
Lymphoproliferative Disorders / pathology
-
Lymphoproliferative Disorders / therapy*
-
Lymphoproliferative Disorders / virology
-
Organ Transplantation*
-
Postoperative Complications / pathology
-
Postoperative Complications / therapy*
-
Postoperative Complications / virology
-
Treatment Outcome
-
Viral Load
Substances
-
Antiviral Agents
-
DNA, Viral
-
Immunosuppressive Agents
-
Interferons